Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity (Q39159252)

9 September 2017

title

Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity (English)

1 reference

9 September 2017

0 references

1 reference

6

Arjan C Lankester

1 reference

9 September 2017

7

Marco W Schilham

1 reference

9 September 2017

5

Maarten J D van Tol

1 reference

9 September 2017

Jens H W Pahl

1

1 reference

9 September 2017

S Eriaty N Ruslan

series ordinal

2

1 reference

9 September 2017

Kitty M C Kwappenberg

series ordinal

3

1 reference

9 September 2017

Monique M van Ostaijen-Ten Dam

series ordinal

4

1 reference

9 September 2017

publication date

27 April 2013

1 reference

Cancer Immunology, Immunotherapy

9 September 2017

published in

1 reference

9 September 2017

volume

62

1 reference

9 September 2017

issue

7

1 reference

9 September 2017

page(s)

1235-1247

1 reference

Ewing's sarcoma family of tumors: current management

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Emerging drugs for high-grade osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration "PALGA".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Line of attack: NK cell specificity and integration of signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Surface NK receptors and their ligands on tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Functions of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

NK cell MHC class I specific receptors (KIR): from biology to clinical intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

ULBP4 is a novel ligand for human NKG2D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

ULBP6/RAET1L is an additional human NKG2D ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Dendritic cells prime natural killer cells by trans-presenting interleukin 15

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

NKG2D function protects the host from tumor initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Impairment of NK cell function by NKG2D modulation in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Human tumor-derived exosomes down-modulate NKG2D expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

NK cells and cancer immunosurveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

The traffic of the NKG2D/Dap10 receptor complex during natural killer (NK) cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1406-X

10.1007/S00262-013-1406-X

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference